Landiolol Hydrochloride Orpha-Devel (Landiolol Hydrochloride)

Landiolol selectively blocks β1‑adrenergic receptors in the heart, reducing cyclic AMP formation and calcium entry into cardiac cells. This leads to decreased myocardial contractility and slower conduction through the sino‑atrial and atrioventricular nodes, thereby lowering heart rate and stabilising rhythm.

The dosing regimen for landiolol is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The infusion rate is titrated to achieve the desired heart‑rate reduction while monitoring for adverse effects.

Safety data for landiolol in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with longer‑acting β‑blockers, landiolol offers an ultra‑short half‑life, allowing rapid titration and immediate cessation of effect after infusion stops. This makes it advantageous in settings where precise heart‑rate control is needed, whereas other agents may have prolonged action and less flexibility.

Landiolol must be stored at 2‑8 °C in a refrigerator, protected from light, and should not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability and potency.

Landiolol is given as an intravenous infusion. The drug is prepared in a sterile diluent and administered through a controlled infusion pump, allowing precise adjustment of the infusion rate according to the patient’s heart‑rate response.

Serious risks include severe bradycardia, hypotension, bronchospasm in patients with reactive airway disease, acute heart failure, and rare cases of anaphylaxis. Continuous cardiac and hemodynamic monitoring is essential to detect and manage these events promptly.

Landiolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, advanced atrioventricular block without a pacemaker, and uncontrolled asthma or chronic obstructive pulmonary disease where β‑blockade could precipitate bronchospasm.